OpenLB
Open Library of Bioscience
Advanced Search
Pharmacology research & perspectives
10, 2021;9 (5): e00778.

Histamine in cancer immunology and immunotherapy. Current status and new perspectives.

Mar��a de la Paz Sarasola, M��nica A T��quez Delgado, Melisa B Nicoud, Vanina A Medina
Author Information
  1. Mar��a de la Paz Sarasola: Laboratory of Tumor Biology and Inflammation, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), and the National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.
  2. M��nica A T��quez Delgado: Laboratory of Tumor Biology and Inflammation, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), and the National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.
  3. Melisa B Nicoud: Laboratory of Tumor Biology and Inflammation, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), and the National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.
  4. Vanina A Medina: Laboratory of Tumor Biology and Inflammation, Institute for Biomedical Research (BIOMED), School of Medical Sciences, Pontifical Catholic University of Argentina (UCA), and the National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina. ORCID
PMID: 34609067 DOI: 10.1002/prp2.778

Abstract

Cancer is the second leading cause of death globally and its incidence and mortality are rapidly increasing worldwide. The dynamic interaction of immune cells and tumor cells determines the clinical outcome of cancer. Immunotherapy comes to the forefront of cancer treatments, resulting in impressive and durable responses but only in a fraction of patients. Thus, understanding the characteristics and profiles of immune cells in the tumor microenvironment (TME) is a necessary step to move forward in the design of new immunomodulatory strategies that can boost the immune system to fight cancer. Histamine produces a complex and fine-tuned regulation of the phenotype and functions of the different immune cells, participating in multiple regulatory responses of the innate and adaptive immunity. Considering the important actions of histamine-producing immune cells in the TME, in this review we first address the most important immunomodulatory roles of histamine and histamine receptors in the context of cancer development and progression. In addition, this review highlights the current progress and foundational developments in the field of cancer immunotherapy in combination with histamine and pharmacological compounds targeting histamine receptors.

Keywords

adaptive immunity anti-tumor immunity breast cancer histamine receptors immunotherapy innate immunity leukemia

References

  1. Cancer Biother Radiopharm. 2006 Dec;21(6):607-12 [PMID: 17257076]
  2. Cancer Immunol Res. 2019 Mar;7(3):388-400 [PMID: 30665890]
  3. Int Immunopharmacol. 2020 Jan;78:106087 [PMID: 31841758]
  4. Cochrane Database Syst Rev. 2009 Oct 07;(4):CD004275 [PMID: 19821323]
  5. J Invest Dermatol. 2004 Jul;123(1):116-23 [PMID: 15191551]
  6. Cancer Immunol Immunother. 2017 Nov;66(11):1473-1484 [PMID: 28721449]
  7. J Immunol. 2007 Jul 1;179(1):365-71 [PMID: 17579057]
  8. J Allergy Clin Immunol. 2009 Mar;123(3):619-25 [PMID: 19281909]
  9. J Immunol. 2007 Jun 15;178(12):8081-9 [PMID: 17548646]
  10. Cell. 2016 Jan 28;164(3):365-77 [PMID: 26806130]
  11. J Biomed Sci. 2019 Oct 20;26(1):78 [PMID: 31629410]
  12. J Biol Regul Homeost Agents. 2013 Jul-Sep;27(3):827-39 [PMID: 24152847]
  13. J Clin Invest. 2014 Dec;124(12):5466-80 [PMID: 25384214]
  14. Biochem Biophys Res Commun. 2000 Dec 20;279(2):615-20 [PMID: 11118334]
  15. Lancet Neurol. 2013 Nov;12(11):1068-75 [PMID: 24107292]
  16. J Clin Oncol. 1999 Jul;17(7):2105-16 [PMID: 10561265]
  17. Semin Cancer Biol. 2012 Aug;22(4):275-81 [PMID: 22313874]
  18. Inflamm Res. 2014 Mar;63(3):239-47 [PMID: 24316866]
  19. Cancer Cell. 2005 May;7(5):411-23 [PMID: 15894262]
  20. Cell Mol Life Sci. 2019 Apr;76(8):1447-1458 [PMID: 30747250]
  21. Nat Rev Immunol. 2020 May;20(5):294-307 [PMID: 31988391]
  22. J Dtsch Dermatol Ges. 2010 Jul;8(7):495-504 [PMID: 20136675]
  23. Ann Oncol. 2002 Mar;13(3):441-9 [PMID: 11996477]
  24. Lancet Neurol. 2017 Mar;16(3):200-207 [PMID: 28129985]
  25. Immunology. 2002 Oct;107(2):217-21 [PMID: 12383201]
  26. J Immunol. 1990 Dec 15;145(12):4365-70 [PMID: 2147942]
  27. J Int Adv Otol. 2015 Aug;11(2):138-42 [PMID: 26381004]
  28. Cancer Res. 2003 Mar 15;63(6):1405-12 [PMID: 12649206]
  29. Br J Cancer. 2020 Feb;122(3):348-360 [PMID: 31748740]
  30. Clin Exp Allergy. 2009 Sep;39(9):1314-23 [PMID: 19538496]
  31. Cancer Med. 2019 Aug;8(10):4709-4721 [PMID: 31222971]
  32. Int J Immunopharmacol. 1992 Jan;14(1):75-81 [PMID: 1582736]
  33. Br Med Bull. 2018 Dec 1;128(1):5-14 [PMID: 30137312]
  34. Mol Pharmacol. 2001 Mar;59(3):427-33 [PMID: 11179435]
  35. Hepatogastroenterology. 2013 Mar-Apr;60(122):244-7 [PMID: 22944376]
  36. J Clin Invest. 2007 Nov;117(11):3507-18 [PMID: 17965772]
  37. Immunol Cell Biol. 2005 Oct;83(5):451-61 [PMID: 16174093]
  38. Cancer Immunol Immunother. 2020 Sep;69(9):1673-1697 [PMID: 32500231]
  39. Oncotarget. 2017 Apr 18;8(16):26471-26491 [PMID: 28460440]
  40. Science. 2003 Feb 14;299(5609):1057-61 [PMID: 12522256]
  41. Cancers (Basel). 2019 Sep 16;11(9): [PMID: 31527531]
  42. Cancer Immunol Res. 2014 Jan;2(1):1-8 [PMID: 24778159]
  43. J Biol Chem. 2011 Mar 4;286(9):6979-88 [PMID: 21205825]
  44. Int J Lab Hematol. 2016 Feb;38(1):42-9 [PMID: 26362346]
  45. Immunol Rev. 2018 Mar;282(1):8-34 [PMID: 29431214]
  46. Biochim Biophys Acta. 2016 Oct;1859(10):1259-68 [PMID: 27424222]
  47. J Allergy Clin Immunol. 2002 May;109(5):839-46 [PMID: 11994709]
  48. J Leukoc Biol. 2015 Oct;98(4):489-96 [PMID: 25632045]
  49. J Clin Pathol. 1981 Dec;34(12):1343-8 [PMID: 7035499]
  50. Oncogene. 2015 Oct 1;34(40):5175-86 [PMID: 25619830]
  51. Cancer Biother Radiopharm. 2012 Sep;27(7):442-5 [PMID: 22731929]
  52. Epilepsy Behav. 2013 Jul;28(1):66-70 [PMID: 23665640]
  53. Cell. 2011 Mar 4;144(5):646-74 [PMID: 21376230]
  54. Pharmacol Res. 2020 Jul;157:104881 [PMID: 32380052]
  55. J Invest Dermatol. 1990 Dec;95(6 Suppl):188S-192S [PMID: 2124246]
  56. Immunity. 2013 Jan 24;38(1):79-91 [PMID: 23273845]
  57. Drugs. 2011 Jan 1;71(1):109-22 [PMID: 21175244]
  58. J Pharmacol Exp Ther. 2003 Jun;305(3):1212-21 [PMID: 12626656]
  59. Br J Pharmacol. 2020 Feb;177(3):469-489 [PMID: 30341770]
  60. J Exp Med. 2008 Nov 24;205(12):2887-98 [PMID: 19001136]
  61. J Immunother Cancer. 2016 Jul 19;4:40 [PMID: 27437104]
  62. Hepatology. 2011 Nov;54(5):1718-28 [PMID: 21793031]
  63. Naunyn Schmiedebergs Arch Pharmacol. 1989 Dec;340(6):671-8 [PMID: 2559336]
  64. J Immunol. 2015 Apr 1;194(7):2985-91 [PMID: 25795789]
  65. Ann Oncol. 2002 Dec;13(12):1919-24 [PMID: 12453861]
  66. Nat Immunol. 2019 Feb;20(2):129-140 [PMID: 30664762]
  67. Int Immunol. 2018 Aug 30;30(9):391-396 [PMID: 30169733]
  68. Scand J Immunol. 2003 Sep;58(3):321-6 [PMID: 12950678]
  69. Int J Mol Sci. 2019 Apr 29;20(9): [PMID: 31035644]
  70. Adv Exp Med Biol. 2020;1224:1-20 [PMID: 32036601]
  71. Mol Pharmacol. 2002 Dec;62(6):1506-14 [PMID: 12435819]
  72. J Innate Immun. 2018;10(4):349-362 [PMID: 30032131]
  73. Eur J Surg Oncol. 1997 Jun;23(3):224-7 [PMID: 9236896]
  74. Melanoma Res. 2003 Jun;13(3):307-11 [PMID: 12777988]
  75. Cancer Immunol Immunother. 2021 Jan;70(1):233-244 [PMID: 32700092]
  76. Cancer Immunol Immunother. 1994 Dec;39(6):416-9 [PMID: 8001030]
  77. Future Oncol. 2008 Apr;4(2):169-77 [PMID: 18407731]
  78. Am J Physiol Gastrointest Liver Physiol. 2019 Jan 1;316(1):G205-G216 [PMID: 30462522]
  79. Oncoimmunology. 2017 Apr 20;6(6):e1317420 [PMID: 28680750]
  80. Cell Mol Immunol. 2017 Aug;14(8):662-674 [PMID: 28626234]
  81. Life (Basel). 2020 Apr 24;10(4): [PMID: 32344736]
  82. J Allergy Clin Immunol. 2011 Dec;128(6):1153-62 [PMID: 21824648]
  83. Blood. 2007 Mar 1;109(5):2058-65 [PMID: 17110462]
  84. Nat Sci Sleep. 2020 Oct 12;12:709-719 [PMID: 33117007]
  85. Cancer Immunol Res. 2016 Feb;4(2):83-91 [PMID: 26839309]
  86. J Clin Oncol. 2002 Jan 1;20(1):125-33 [PMID: 11773161]
  87. J Rheumatol. 2016 Sep;43(9):1637-42 [PMID: 27422891]
  88. Front Immunol. 2018 Aug 15;9:1894 [PMID: 30158936]
  89. Cancer Immunol Immunother. 2007 Apr;56(4):573-80 [PMID: 16896966]
  90. Nat Rev Clin Oncol. 2017 Jul;14(7):399-416 [PMID: 28117416]
  91. J Allergy Clin Immunol. 2011 Apr;127(4):943-53.e1-10 [PMID: 21269673]
  92. Cancer Sci. 2011 Jan;102(1):137-43 [PMID: 20973869]
  93. Curr Opin Immunol. 2017 Oct;48:108-113 [PMID: 28923468]
  94. Br J Pharmacol. 2020 Feb;177(3):490-502 [PMID: 30460986]
  95. J Clin Med. 2020 Jan 14;9(1): [PMID: 31947592]
  96. Eur J Haematol. 1996 Oct;57(4):312-9 [PMID: 8982295]
  97. Genes Cells. 2016 Jun;21(6):624-38 [PMID: 27169545]
  98. Eur J Cancer. 2014 Apr;50(6):1195-206 [PMID: 24447834]
  99. Br J Pharmacol. 2020 Feb;177(3):516-538 [PMID: 30414378]
  100. Int Immunol. 2009 Oct;21(10):1105-11 [PMID: 19737784]
  101. Trends Cancer. 2016 Nov;2(11):664-675 [PMID: 28741505]
  102. Nat Med. 2019 Mar;25(3):377-388 [PMID: 30842679]
  103. Mol Pharmacol. 2006 Aug;70(2):450-3 [PMID: 16723495]
  104. Trends Immunol. 2016 Jan;37(1):41-52 [PMID: 26700397]
  105. Clin Transl Oncol. 2019 Jun;21(6):713-720 [PMID: 30446984]
  106. Semin Immunol. 2020 Jun;49:101436 [PMID: 33288379]
  107. Nat Commun. 2017 Jul 17;8:16073 [PMID: 28714465]
  108. Blood. 2016 Aug 11;128(6):763-73 [PMID: 27354720]
  109. Cancer Immunol Immunother. 2004 Aug;53(8):729-39 [PMID: 15088127]
  110. Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106 [PMID: 29149325]
  111. Br J Pharmacol. 2004 Feb;141(4):552-61 [PMID: 14744809]
  112. Pharmacol Rev. 1997 Sep;49(3):253-78 [PMID: 9311023]
  113. J Biol Chem. 1989 Nov 5;264(31):18356-62 [PMID: 2553705]
  114. Semin Immunol. 2018 Feb;35:29-34 [PMID: 29428698]
  115. Chem Rev. 2011 Nov 9;111(11):7121-56 [PMID: 21842846]
  116. Cells. 2020 Jul 07;9(7): [PMID: 32645919]
  117. J Pharmacol Exp Ther. 2000 Oct;295(1):219-25 [PMID: 10991982]
  118. J Pharmacol Exp Ther. 2014 Dec;351(3):519-26 [PMID: 25273276]
  119. Nature. 1972 Apr 21;236(5347):385-90 [PMID: 4401751]
  120. Front Immunol. 2019 Apr 18;10:771 [PMID: 31057536]
  121. Therap Adv Gastroenterol. 2020 Jun 1;13:1756284820917527 [PMID: 32536977]
  122. J Clin Pathol. 2001 Dec;54(12):940-4 [PMID: 11729214]
  123. J Thorac Cardiovasc Surg. 2001 Jun;121(6):1058-63 [PMID: 11385371]
  124. Nature. 2001 Sep 27;413(6854):420-5 [PMID: 11574888]
  125. Eur J Clin Invest. 2018 Oct;48(10):e13000 [PMID: 30019447]
  126. Naunyn Schmiedebergs Arch Pharmacol. 2012 Feb;385(2):125-35 [PMID: 22071576]
  127. J Leukoc Biol. 2018 Mar;103(3):457-464 [PMID: 29345348]
  128. FEBS Lett. 1997 Jun 9;409(2):283-6 [PMID: 9202162]
  129. Clin Exp Allergy. 2009 Dec;39(12):1786-800 [PMID: 20085595]
  130. Allergy. 2016 Sep;71(9):1264-73 [PMID: 26948974]
  131. Cancer Invest. 2000;18(4):347-55 [PMID: 10808371]
  132. J Surg Oncol. 2021 Mar;123(3):730-738 [PMID: 33259653]
  133. J Dermatol. 2015 Feb;42(2):129-39 [PMID: 25491792]
  134. Oncotarget. 2016 Mar 8;7(10):10891-904 [PMID: 26863636]
  135. Oncotarget. 2016 Feb 16;7(7):7842-55 [PMID: 26556868]
  136. Br J Cancer. 2005 Oct 3;93(7):757-62 [PMID: 16136045]
  137. Cytokine Growth Factor Rev. 2007 Feb-Apr;18(1-2):5-17 [PMID: 17321783]
  138. Mol Immunol. 2015 Jan;63(1):113-24 [PMID: 24698842]
  139. J Clin Pharmacol. 2002 Jul;42(7):774-81 [PMID: 12092744]
  140. Mol Immunol. 2019 Jun;110:40-47 [PMID: 29233542]
  141. Cancer Cell. 2010 Feb 17;17(2):121-34 [PMID: 20138013]
  142. Neoplasia. 2012 Jul;14(7):572-84 [PMID: 22904675]
  143. Anticancer Res. 2004 May-Jun;24(3b):1837-42 [PMID: 15274364]
  144. Am J Physiol. 1994 Aug;267(2 Pt 2):R602-11 [PMID: 7915087]
  145. Clin Cancer Res. 2011 Aug 1;17(15):4987-95 [PMID: 21690573]
  146. Front Immunol. 2018 Mar 02;9:398 [PMID: 29552012]
  147. Br J Haematol. 1996 Mar;92(3):620-6 [PMID: 8616026]
  148. Oncogene. 2020 Feb;39(8):1724-1738 [PMID: 31740780]
  149. Anticancer Agents Med Chem. 2018;18(1):15-20 [PMID: 26996193]
  150. Eur J Pharmacol. 2019 Mar 15;847:42-52 [PMID: 30685431]
  151. J Biol Chem. 2000 Nov 24;275(47):36781-6 [PMID: 10973974]
  152. Cancer. 1997 Jun 15;79(12):2320-8 [PMID: 9191519]
  153. Front Oncol. 2019 Nov 21;9:1280 [PMID: 31824856]
  154. Inflammation. 1983 Sep;7(3):291-300 [PMID: 6681322]
  155. Inflamm Res. 2018 Jun;67(6):503-513 [PMID: 29600327]
  156. Oncoimmunology. 2015 May 05;5(1):e1041701 [PMID: 26942055]
  157. Cancer Biother Radiopharm. 2011 Feb;26(1):65-7 [PMID: 21348776]
  158. Inflamm Bowel Dis. 2016 Jul;22(7):1575-86 [PMID: 27271490]
  159. Nature. 2011 Jul 13;475(7355):226-30 [PMID: 21753853]
  160. Nat Rev Immunol. 2004 Dec;4(12):941-52 [PMID: 15573129]
  161. Front Pharmacol. 2019 Jun 05;10:556 [PMID: 31231212]
  162. J Cell Biol. 2015 Aug 31;210(5):851-64 [PMID: 26304724]
  163. Lung Cancer. 2012 Jan;75(1):38-44 [PMID: 21733595]
  164. Mod Pathol. 2006 Jan;19(1):149-59 [PMID: 16258517]
  165. Oncotarget. 2015 Dec 15;6(40):42569-74 [PMID: 26544512]
  166. J Pharmacol Exp Ther. 2014 Jul;350(1):181-7 [PMID: 24817035]
  167. Cancer. 2000 Feb 1;88(3):577-83 [PMID: 10649250]
  168. Nature. 2019 Oct;574(7776):45-56 [PMID: 31578484]
  169. J Clin Invest. 2001 Dec;108(12):1865-73 [PMID: 11748270]
  170. Br J Cancer. 2000 Sep;83(6):826-32 [PMID: 10952789]
  171. Endokrynol Pol. 2018;69(6):722-733 [PMID: 30618030]
  172. J Pharmacol Sci. 2005 Jan;97(1):116-23 [PMID: 15655289]
  173. Pharmacol Res Perspect. 2021 Oct;9(5):e00778 [PMID: 34609067]
  174. Leuk Lymphoma. 1997 Nov;27(5-6):429-38 [PMID: 9477124]
  175. Br J Pharmacol. 1997 Feb;120(4 Suppl):302-14, discussion 300-1 [PMID: 9142412]
  176. Scand J Immunol. 2013 Feb;77(2):84-91 [PMID: 23298196]
  177. Asian Pac J Cancer Prev. ;18(7):1827-1832 [PMID: 28749113]
  178. Melanoma Res. 2000 Feb;10(1):66-77 [PMID: 10711642]
  179. mBio. 2018 Nov 13;9(6): [PMID: 30425146]
  180. Cancer Biother Radiopharm. 2009 Apr;24(2):181-3 [PMID: 19409039]
  181. Eur J Surg Oncol. 1995 Oct;21(5):526-30 [PMID: 7589599]
  182. Cancer Biol Med. 2018 Aug;15(3):189-209 [PMID: 30197788]
  183. Blood. 2006 Oct 1;108(7):2290-9 [PMID: 16794249]
  184. World J Urol. 2021 May;39(5):1387-1403 [PMID: 33106940]
  185. Biochem Pharmacol. 2007 Apr 15;73(8):1195-204 [PMID: 17276412]
  186. J Cell Physiol. 2018 Apr;233(4):3024-3036 [PMID: 28661031]
  187. J Neurooncol. 2015 Jul;123(3):323-30 [PMID: 26070552]
  188. J Recept Signal Transduct Res. 2002 Feb-Nov;22(1-4):431-48 [PMID: 12503632]
  189. Mol Pharmacol. 2013 May;83(5):1087-98 [PMID: 23462507]
  190. J Leukoc Biol. 2014 Sep;96(3):411-8 [PMID: 24799603]
  191. J Immunol. 2015 May 15;194(10):5014-21 [PMID: 25870245]
  192. J Leukoc Biol. 2017 Aug;102(2):467-474 [PMID: 28235771]
  193. Life Sci. 2020 Aug 1;254:117580 [PMID: 32205087]
  194. Atherosclerosis. 2017 Aug;263:42-52 [PMID: 28600950]
  195. Br J Haematol. 2000 Mar;108(3):565-73 [PMID: 10759715]
  196. Cancer Immunol Immunother. 2019 May;68(5):823-833 [PMID: 30302498]
  197. Cancer Immunol Res. 2013 Nov;1(5):269-79 [PMID: 24777963]
  198. Science. 2020 May 29;368(6494):973-980 [PMID: 32467386]
  199. Br J Cancer. 2002 Jul 15;87(2):194-201 [PMID: 12107842]
  200. Int J Mol Med. 2004 Feb;13(2):203-9 [PMID: 14719124]
  201. Oncotarget. 2015 Jun 10;6(16):14179-90 [PMID: 25895025]
  202. Biochem Pharmacol. 2016 Mar 1;103:74-84 [PMID: 26774453]
  203. Support Care Cancer. 2003 May;11(5):304-12 [PMID: 12720074]
  204. Microbiologyopen. 2019 Oct;8(10):e908 [PMID: 31369218]
  205. J Pharmacol Exp Ther. 2001 Mar;296(3):1058-66 [PMID: 11181941]
  206. Naunyn Schmiedebergs Arch Pharmacol. 2009 Apr;379(4):427-34 [PMID: 19145429]
  207. Cancer Biother Radiopharm. 2006 Oct;21(5):515-9 [PMID: 17105423]
  208. J Pharmacol Sci. 2007 Sep;105(1):66-73 [PMID: 17895589]
  209. Semin Oncol. 2002 Jun;29(3 Suppl 7):35-40 [PMID: 12068387]
  210. J Immunol. 2005 May 1;174(9):5224-32 [PMID: 15843518]
  211. Trends Immunol. 2019 Aug;40(8):699-718 [PMID: 31301952]
  212. Precis Clin Med. 2018 Sep;1(2):65-74 [PMID: 30687562]
  213. Am J Pathol. 2017 Oct;187(10):2323-2336 [PMID: 28917668]
  214. Br J Haematol. 2020 Feb;188(4):e49-e53 [PMID: 31853942]
  215. Scand J Immunol. 2009 Sep;70(3):194-205 [PMID: 19703009]
  216. Mediators Inflamm. 2018 Aug 27;2018:9524075 [PMID: 30224900]
  217. PLoS One. 2012;7(2):e31207 [PMID: 22363581]
  218. Front Immunol. 2020 Sep 18;11:1624 [PMID: 33042104]
  219. Oncotarget. 2016 Jul 19;7(29):46466-46481 [PMID: 27341131]
  220. Hematol J. 2003;4(5):336-41 [PMID: 14502258]
  221. J Clin Oncol. 1985 Jul;3(7):977-81 [PMID: 4020408]
  222. Blood Rev. 2013 Sep;27(5):209-16 [PMID: 23871358]
  223. J Immunol. 2006 Jun 1;176(11):7062-70 [PMID: 16709868]
  224. Cytokine. 2019 May;117:30-40 [PMID: 30784898]
  225. FEBS J. 2021 Jan;288(1):229-243 [PMID: 32333821]
  226. Expert Opin Ther Targets. 2019 Feb;23(2):127-142 [PMID: 30556751]
  227. J Cell Biochem. 2019 Mar;120(3):2756-2765 [PMID: 30270458]
  228. Cell. 2019 Apr 18;177(3):556-571.e16 [PMID: 30955881]
  229. Cancer Res. 2011 May 15;71(10):3505-15 [PMID: 21444674]
  230. Int Arch Allergy Immunol. 2005 May;137(1):82-92 [PMID: 15832054]
  231. Br J Pharmacol. 2010 Oct;161(4):755-67 [PMID: 20636392]
  232. Nat Med. 2011 Jan;17(1):87-95 [PMID: 21170045]
  233. Clin Sci (Lond). 1994 Aug;87(2):151-63 [PMID: 7924160]
  234. Cancer Biother Radiopharm. 2005 Oct;20(5):487-90 [PMID: 16248764]
  235. Chem Immunol Allergy. 2006;91:174-87 [PMID: 16354958]
  236. Pol Merkur Lekarski. 2006 Mar;20(117):318-21 [PMID: 16780265]
  237. PLoS One. 2017 Apr 26;12(4):e0176460 [PMID: 28445506]
  238. Lancet Oncol. 2018 Jan;19(1):40-50 [PMID: 29233559]
  239. Immunity. 2009 May;30(5):636-45 [PMID: 19464986]
  240. Curr Opin Immunol. 2017 Apr;45:43-51 [PMID: 28192720]
  241. Cells. 2019 Jul 19;8(7): [PMID: 31331034]
  242. Curr Med Chem. 2016;23(7):650-66 [PMID: 26785997]
  243. Br J Pharmacol. 2009 May;157(1):14-23 [PMID: 19413568]
  244. Trends Cancer. 2018 Nov;4(11):784-792 [PMID: 30352680]
  245. Br J Pharmacol. 2013 Sep;170(1):188-99 [PMID: 23425150]
  246. Naunyn Schmiedebergs Arch Pharmacol. 2012 Sep;385(9):853-4; author reply 855-60 [PMID: 22411357]
  247. Am J Pathol. 2012 Jan;180(1):177-85 [PMID: 22063299]
  248. Cancer Biother Radiopharm. 2005 Feb;20(1):36-40 [PMID: 15778577]
  249. FEBS J. 2018 Dec;285(23):4316-4342 [PMID: 29851227]
  250. Br J Cancer. 1998 Apr;77(8):1213-9 [PMID: 9579825]
  251. J Allergy Clin Immunol. 2019 May;143(5):1830-1837.e4 [PMID: 30414855]
  252. J Allergy Clin Immunol. 2013 Jul;132(1):194-204 [PMID: 23465664]
  253. Int Rev Cell Mol Biol. 2019;348:123-178 [PMID: 31810552]
  254. J Exp Med. 2013 Aug 26;210(9):1711-28 [PMID: 23897983]
  255. J Pharmacol Exp Ther. 2002 Oct;303(1):300-7 [PMID: 12235264]
  256. Biochim Biophys Acta Mol Basis Dis. 2017 Nov;1863(11):2954-2963 [PMID: 28847511]
  257. Cancer Cell. 2009 Sep 8;16(3):183-94 [PMID: 19732719]
  258. J Immunol. 2009 Sep 1;183(5):3014-22 [PMID: 19667094]
  259. Adv Exp Med Biol. 2017;1036:105-128 [PMID: 29275468]
  260. Cancers (Basel). 2020 Apr 08;12(4): [PMID: 32276475]
  261. Clin Ther. 2015 Oct 1;37(10):2352-64 [PMID: 26276501]
  262. J Pharmacol Exp Ther. 2014 May;349(2):176-84 [PMID: 24549371]
  263. Nat Rev Drug Discov. 2008 Jan;7(1):41-53 [PMID: 18172439]
  264. Scand J Clin Lab Invest. 1997 May;57(3):193-202 [PMID: 9238754]
  265. Pharmacol Rev. 2015 Jul;67(3):601-55 [PMID: 26084539]
  266. Cancer Microenviron. 2015 Dec;8(3):167-76 [PMID: 25194694]
  267. Cold Spring Harb Perspect Biol. 2018 Dec 3;10(12): [PMID: 29101107]
  268. Cancer Invest. 2011 May;29(4):293-9 [PMID: 21469978]
  269. Ann Allergy Asthma Immunol. 2018 Nov;121(5):568-574 [PMID: 30102965]
  270. J Immunol. 2008 May 1;180(9):5916-26 [PMID: 18424711]
  271. J Immunol. 2007 Dec 1;179(11):7907-15 [PMID: 18025238]
  272. Front Immunol. 2019 Jul 31;10:1818 [PMID: 31417576]
  273. Br J Cancer. 2006 Jan 30;94(2):218-26 [PMID: 16434984]
  274. Life Sci. 2003 Oct 31;73(24):3043-72 [PMID: 14550847]
  275. Exp Dermatol. 2000 Apr;9(2):118-24 [PMID: 10772385]
  276. J Immunol. 2001 Oct 1;167(7):3682-6 [PMID: 11564782]
  277. Cancers (Basel). 2016 Feb 20;8(2): [PMID: 26907350]
  278. Handb Exp Pharmacol. 2017;241:301-320 [PMID: 28233185]
  279. Cancer Biother Radiopharm. 2010 Apr;25(2):179-83 [PMID: 20423231]
  280. Exp Dermatol. 2015 Apr;24(4):280-4 [PMID: 25651189]
  281. J Clin Oncol. 2011 May 20;29(15):1949-55 [PMID: 21483002]
  282. Handb Exp Pharmacol. 2017;241:141-160 [PMID: 27316911]
  283. Immunol Lett. 2019 May;209:28-35 [PMID: 30905824]
  284. Clin Rev Allergy Immunol. 2020 Jun;58(3):377-387 [PMID: 32086776]
  285. Cancer Biother Radiopharm. 2008 Feb;23(1):108-13 [PMID: 18298334]
  286. Trends Immunol. 2016 Mar;37(3):208-220 [PMID: 26858199]
  287. FEBS Lett. 2000 May 19;473(3):345-8 [PMID: 10818238]
  288. Cancer Biother Radiopharm. 2008 Oct;23(5):641-6 [PMID: 18999936]
  289. Oral Dis. 2021 Jul;27(5):1090-1096 [PMID: 32395857]
  290. Hum Vaccin Immunother. 2020;16(1):109-111 [PMID: 31242079]
  291. Cell. 2000 Jan 7;100(1):57-70 [PMID: 10647931]
  292. Scand J Immunol. 2010 Dec;72(6):540-7 [PMID: 21044128]
  293. J Allergy Clin Immunol. 2002 Mar;109(3):524-31 [PMID: 11898002]
  294. J Mol Med (Berl). 2018 Sep;96(9):951-964 [PMID: 30058054]
  295. Am J Rhinol Allergy. 2014 May-Jun;28(3):e130-5 [PMID: 24980224]
  296. Nature. 2010 Mar 11;464(7286):302-5 [PMID: 20220849]
  297. Semin Oncol. 2010 Oct;37(5):430-9 [PMID: 21074057]
  298. Semin Cancer Biol. 2021 Jan;68:199-208 [PMID: 32044470]
  299. Circ Res. 2004 Jan 9;94(1):17-27 [PMID: 14715532]
  300. Mol Ther Methods Clin Dev. 2017 Mar 18;5:66-75 [PMID: 28480306]
  301. Clin Cancer Res. 2005 Jan 1;11(1):290-7 [PMID: 15671558]
  302. Cancer Res. 2014 Sep 15;74(18):5091-102 [PMID: 25224959]
  303. FEBS J. 2005 Jun;272(12):2939-46 [PMID: 15955054]
  304. Cancer. 1987 Feb 1;59(3 Suppl):638-46 [PMID: 10822463]
  305. Br J Pharmacol. 2019 Dec;176 Suppl 1:S21-S141 [PMID: 31710717]
  306. Expert Opin Biol Ther. 2009 Sep;9(9):1217-23 [PMID: 19653866]
  307. Cell. 2012 Jul 6;150(1):165-78 [PMID: 22770218]
  308. Anticancer Res. 2003 Jan-Feb;23(1B):537-42 [PMID: 12680142]
  309. Front Oncol. 2018 Mar 28;8:86 [PMID: 29644214]
  310. Virchows Arch. 2017 May;470(5):505-515 [PMID: 28315938]
  311. Clin Immunol Immunopathol. 1994 Oct;73(1):96-102 [PMID: 7923922]
  312. Anticancer Res. 1999 May-Jun;19(3A):1961-9 [PMID: 10470141]
  313. Br J Pharmacol Chemother. 1956 Dec;11(4):472-3 [PMID: 13383131]
  314. J Clin Invest. 2007 May;117(5):1137-46 [PMID: 17476343]
  315. Int Arch Allergy Immunol. 2001 Jan-Mar;124(1-3):249-52 [PMID: 11306983]
  316. Nature. 1983 Apr 28;302(5911):832-7 [PMID: 6188956]
  317. Cancer Treat Rev. 2012 Dec;38(8):943-55 [PMID: 22651904]
  318. Allergy. 1992 Dec;47(6):624-9 [PMID: 1285569]
  319. Int Immunopharmacol. 2019 May;70:156-166 [PMID: 30802678]
  320. J Immunol. 1986 Jul 15;137(2):656-60 [PMID: 3722819]
  321. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2796-801 [PMID: 21825174]
  322. CA Cancer J Clin. 2018 Nov;68(6):394-424 [PMID: 30207593]
  323. Trends Pharmacol Sci. 2013 Jan;34(1):33-58 [PMID: 23254267]
  324. J Immunol. 2012 Jan 15;188(2):541-7 [PMID: 22147765]
  325. Haematologica. 2012 Dec;97(12):1904-8 [PMID: 22689678]
  326. Scand J Immunol. 2016 Jun;83(6):409-17 [PMID: 26900758]
  327. Transl Gastrointest Cancer. 2012 Oct;1(3):215-227 [PMID: 24639917]
  328. Cells. 2019 May 13;8(5): [PMID: 31086070]
  329. Trends Pharmacol Sci. 2013 Jan;34(1):13-32 [PMID: 23228711]
  330. Phytother Res. 2019 Jul;33(7):1878-1887 [PMID: 31140641]
  331. Cancer Immunol Immunother. 2019 Feb;68(2):163-174 [PMID: 30315349]
  332. Leukemia. 2017 Dec;31(12):2552-2559 [PMID: 28529313]
  333. Blood. 2006 Oct 15;108(8):2712-9 [PMID: 16809616]
  334. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10146-51 [PMID: 17548817]
  335. In Vivo. 2019 May-Jun;33(3):743-748 [PMID: 31028192]
  336. Cell Immunol. 2019 Sep;343:103753 [PMID: 29395859]
  337. Life Sci. 2017 Mar 1;172:27-41 [PMID: 27986539]
  338. Ann Oncol. 2007 Oct;18(10):1691-7 [PMID: 17709802]
  339. Front Oncol. 2018 Jun 18;8:218 [PMID: 29967760]
  340. Oncotarget. 2016 Feb 16;7(7):7586-96 [PMID: 26863635]
  341. Haematologica. 2011 Aug;96(8):1106-12 [PMID: 21546500]
  342. Stem Cell Res Ther. 2020 Mar 4;11(1):27 [PMID: 32127042]
  343. J Cancer Res Clin Oncol. 2006 Aug;132(8):499-504 [PMID: 16586071]
  344. Immunol Rev. 2011 Jul;242(1):144-60 [PMID: 21682743]
  345. Mol Pharmacol. 2002 Aug;62(2):389-97 [PMID: 12130692]
  346. Front Immunol. 2018 Dec 20;9:3059 [PMID: 30619378]
  347. J Immunol Res. 2016;2016:4684268 [PMID: 27294158]
  348. PLoS One. 2015 Feb 27;10(2):e0114831 [PMID: 25723478]
  349. Lancet. 1988 Oct 29;2(8618):990-2 [PMID: 2902494]
  350. Cancer Biother Radiopharm. 2014 Mar;29(2):58-61 [PMID: 24251758]
  351. J Gastroenterol. 2009;44(4):285-96 [PMID: 19277450]
  352. Mol Pharmacol. 2001 Mar;59(3):420-6 [PMID: 11179434]
  353. Biochem Biophys Res Commun. 2008 Aug 1;372(3):491-6 [PMID: 18502198]
  354. Allergy. 2004 Mar;59(3):268-75 [PMID: 14982507]
  355. J Leukoc Biol. 2014 Jul;96(1):151-9 [PMID: 24610880]
  356. Immunology. 2012 May;136(1):103-14 [PMID: 22304689]
  357. Expert Rev Mol Med. 2003 Jan 13;5(3):1-19 [PMID: 14987405]
  358. J Dermatol Sci. 2016 Aug;83(2):106-15 [PMID: 27155791]
  359. Cancer Microenviron. 2013 Aug;6(2):123-33 [PMID: 23242673]
  360. Biochem Pharmacol. 2012 Nov 1;84(9):1174-85 [PMID: 22922404]
  361. J Allergy Clin Immunol. 2005 Nov;116(5):961-8; quiz 969 [PMID: 16275361]
  362. Nat Rev Immunol. 2019 Jun;19(6):369-382 [PMID: 30718830]
  363. Cancer Biother Radiopharm. 2009 Feb;24(1):1-6 [PMID: 19243244]
  364. J Drugs Dermatol. 2018 Aug 1;17(8):873-879 [PMID: 30124726]
  365. Nat Rev Immunol. 2012 Mar 22;12(4):253-68 [PMID: 22437938]
  366. Br J Cancer. 2019 Jan;120(1):128-138 [PMID: 29988113]
  367. Biochem Biophys Res Commun. 2001 Jun 8;284(2):301-9 [PMID: 11394877]
  368. Curr Opin Immunol. 2008 Apr;20(2):149-57 [PMID: 18434123]
  369. Transl Cancer Res. 2017 Feb;6(1):93-103 [PMID: 28955654]
  370. Blood. 2019 May 16;133(20):2159-2167 [PMID: 30898857]
  371. Cancer Immunol Immunother. 2012 Sep;61(9):1527-34 [PMID: 22706380]

MeSH Term

Adaptive Immunity
Antineoplastic Agents, Immunological
B-Lymphocytes
Basophils
Histamine
Humans
Immunity, Innate
Immunotherapy
Killer Cells, Natural
Lymphocytes, Tumor-Infiltrating
Macrophages
Mast Cells
Neoplasms
Neutrophils
Receptors, Histamine
T-Lymphocytes
Tumor Microenvironment

Chemicals

Antineoplastic Agents, Immunological
Receptors, Histamine
Histamine
Journal Article Research Support, Non-U.S. Gov't Review
Article has an altmetric score of 2

Word Cloud

Created with Highcharts 10.0.0cancerimmunecellshistamineimmunityreceptorsimmunotherapytumorresponsesTMEnewimmunomodulatoryHistamineinnateadaptiveimportantreviewCancersecondleadingcausedeathgloballyincidencemortalityrapidlyincreasingworldwidedynamicinteractiondeterminesclinicaloutcomeImmunotherapycomesforefronttreatmentsresultingimpressivedurablefractionpatientsThusunderstandingcharacteristicsprofilesmicroenvironmentnecessarystepmoveforwarddesignstrategiescanboostsystemfightproducescomplexfine-tunedregulationphenotypefunctionsdifferentparticipatingmultipleregulatoryConsideringactionshistamine-producingfirstaddressrolescontextdevelopmentprogressionadditionhighlightscurrentprogressfoundationaldevelopmentsfieldcombinationpharmacologicalcompoundstargetingimmunologyCurrentstatusperspectivesanti-tumorbreastleukemia

Similar Articles

Cited By